Karen 是 Certara UK Limited 旗下 Simcyp 事业部的客户与监管战略高级副总裁。Prior to this, she was the Head of PBPK Consultancy Services at Simcyp where she led a team of scientists engaged in Consultancy projects relating to the application of physiologically based pharmacokinetic (PBPK) modelling in drug development. Her work has focused on the use of PBPK models for assessment of drug-drug interactions and dosing of special populations and she is the author/co-author of more than 100 peer reviewed articles in these areas.
Karen Rowland Yeo, PhD
高级副总裁,客户与监管战略部
相关资源
The Power of Modeling: Speed, Early De-Risking, and Regulatory Success for Forward-Thinking Sponsors
网络研讨会点播
机制性 MIDD:凭借坚实的科学基础实现监管成功
现场活动
The Modeling Advantage: How Forward-Thinking Sponsors Are Moving Faster, De-Risking Earlier, and Winning with Regulators
网络研讨会点播
PBPK Modeling in Pregnancy: Improving Drug Dosing Without Clinical Trials
新闻报导
Final ICH M15 Guidance: Aligning MIDD with Global Regulatory Expectations
网络研讨会点播
